EUCTR2007-000567-26-IT进行中（未招募）1 期
Phase II Trial for the Treatment of Advanced Classical Kaposi?s Sarcoma with the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy - ND
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All subjects enrolled in this study must: - have a documented diagnosis of KS; - be HIV-negative as proven by approved test [enzyme-linked immunosorbent assay (ELISA) antibody at screening]; - be classified as a stage III or IV; - be 18 years old; - have stopped every other anti-KS therapy since at least 2 weeks; - be informed of the nature of the study and have provided written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any one or more of the following are cause for exclusion from the study: - inability to give informed consent; - other concomitant illness, neoplasia, with the exception of small non-melanoma skin cancers, or any other clinical condition threatening the health of the patient or his compliance to the treatment; - concomitant treatment (within 2 weeks of initiating study treatment) with systemic immunomodulatory agents (e.g., glucocorticoids as immunosuppressive agents, interferons) or chemotherapy; - pregnancy [confirmed by a positive urine/serum beta human chorionic gonadropinHCG) test]. Patients who became pregnant during the study will be discontinued from the study; - severe restrictive bronchopneumopathies, interstitial fibrosis, chronic asthma or bronchitis; - previous total load of systemic Bleomycin >90 mg; - monolateral nephropathy or history of nephrolitiasis in the last 5 years; - any clinically significant and persistent laboratory findings obtained during screening, including: alkaline phosphatase (AP), aspartate aminotransferase (AST), alkaline aminotransferase (ALT), -glutamyl transferase (-GT) or total bilirubin >3 fold upper limit of normal (ULN); pancreatic amylase >1.5 folds ULN; hemoglobin <10.0 g/dL for males, <9.0 g/dL for females; platelet count <100.000/cubic millimeter (mm3); neutrophil count <1500/mm3; uricemia >6 mg/dl, proteinuria >300 mg/day loss, microscopic hematuria presents in 3 consecutive samples in the absence of urinary infection; serum creatinine >1.2 mg/d for women and >1.4 mg/dL for men or creatinine clearance > 100 + 25, Only in patients over sixty years old creatinine clearance will be calculated according to the Cochroft?s formula that is for men: (140 - age of patient) x ideal weight = creatinine clearance 72 x plasmatic creatinine For women the same formula will be multiplied for 0.85. In these patients creatinine clearance must be > 50 mg/min. If creatinine clearance <50 mg/min they must be excluded from the study; - difficulty in swallowing capsules/tablets; Previous treatment with Indinavir is not an exclusion criterion.
研究者
相似试验
进行中（未招募）
1 期
Ensayo Clínico abierto, fase II, de tratamiento neo-adyuvante de Sunitinib (SU11248) previo al tratamiento con irradiación y concomitante a la misma, en pacientes con Glioblastoma RPA-V-VI y sólo biopsiaGlioblastoma clase RPA V-VI, no resecableEUCTR2008-006728-73-ESGRUPO ESPAÑOL DE NEUROONCOLOGIA MEDICA36
进行中（未招募）
不适用
?Estudio de fase II de tratamiento neoadyuvante con gemcitabina, Tarceva® y oxaliplatino, seguido de quimiorradioterapia con Tarceva® y gemcitabina en pacientes con adenocarcinoma pancreático de resecabilidad borderline?.PHASE II STUDY OF NEOADYUVANT TREATMENT WITH GEMCITSBINE, TARCEVA AND OXALIPLATIN FOLLOWED BY CHEMORADIOTERAPY WITH TARCEVA AND GEMCITABINE IN PATIENTS WITH PANCREAS ADENOCARCINOMA WITH BORDERLINE RESECABILITY - GEMERLOXAEUCTR2010-021872-27-ESInstitut Català d?Oncologia (ICO)
已完成
2 期
Phase II trial of early secondary treatment with nibolumab for non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000030457Fujita Health University School30
已完成
4 期
To check the efficacy of a new nanoform bone healing material in the clinical management of severe gum diseaseCTRI/2017/03/008162I30
进行中（未招募）
不适用
Clinical trial in patients with metastatic colorectal Cancer to evaluate the response of removable liver metastases after treatment with Cetuximab (Erbitux).EUCTR2013-002347-28-ESACROSS: Associació Catalana per a la Recerca Oncològica i les seves implicacions sanitàries i Socials